.jpg "Aquinox Pharmaceuticals (NASDAQ: AQXP)")
Aquinox Pharmaceuticals (NASDAQ: AQXP) received a Hold rating and a $2 price target from Cantor Fitzgerald analyst William Tanner today. The company’s shares opened today at $2.68, close to its 52-week low of $2.25.
Tanner wrote:
“: We are downgrading our opinion of AQXP stock from and we are lowering our PT from $28 to $2. LEADERSHIP-301 trial and the decision to discontinue all rosiptor development leaves the company with little value other than cash, in our opinion.”
According to TipRanks.com, Tanner is a 4-star analyst with an average return of 9.0% and a 56.5% success rate. Tanner covers the Healthcare sector, focusing on stocks such as Synergy Pharmaceuticals Inc, Supernus Pharmaceuticals, and Intra-Cellular Therapies.
Currently, the analyst consensus on Aquinox Pharmaceuticals is a Strong Buy with an average price target of $25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.90 and a one-year low of $2.25. Currently, Aquinox Pharmaceuticals has an average volume of 91.09K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.
Read More on AQXP:
